Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17489077 | 0.84 | KDM4E (0.40) | ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2797118 | 0.82 | LMNA (0.36) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL25007588 | 0.79 | NPC1 (0.44) | ALDH1A1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL12988500 | 0.78 | P2RX7 (0.41) | ALDH1A1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL21166116 | 0.74 | CNR1 (0.33) | ALDH1A1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL2629340 | 0.72 | — | — | |
| SCHEMBL24802088 | 0.72 | GAA (0.43) | ALDH1A1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL20462591 | 0.72 | CYP4F2 (0.40) | ALDH1A1CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL17454448 | 0.72 | ALDH1A1 (0.38) | ALDH1A1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL18158130 | 0.71 | SCN9A (0.34) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3357921-A2 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Sunesis Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9856244-B2 | Dihydropyridinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| EP-3114121-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | Bristol-Myers Squibb Company (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015134701-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134701-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015089337-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20090280084-A1 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2009-11-12 | — | — | US | disclosed |
| US-7365057-B2 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | ALDH1A1 374/4885KMT2A 1779/4885CYP4F2 292/4885 |
| US-20090280084-A1 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | PNP, NUDT1, RNMT | ALDH1A1 3010/4885KMT2A 4191/4885CYP4F2 2527/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | ALDH1A1 1320/4885KMT2A 1471/4885CYP4F2 1283/4885 |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | DGAT2, MGAT2, DGAT1 | ALDH1A1 611/4885KMT2A 300/4885CYP4F2 450/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ALDH1A1 1320/4885KMT2A 1471/4885CYP4F2 1283/4885 |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ALDH1A1 2714/4885KMT2A 2207/4885CYP4F2 3814/4885 |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | DGAT2, DGAT1, MGAT2 | ALDH1A1 372/4885KMT2A 224/4885CYP4F2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.